Graybug Vision discloses supplemental merger details, CMO Parisa Zamiri terminated ahead of CalciMedica merger

CalciMedica, Inc.

CMO Parisa Zamiri terminated Feb 28, 2023; receives $829,084 severance, COBRA, and stock acceleration.
Zamiri also signed consulting agreement at $350/hr up to 8 hrs/week through May 21, 2023.
Supplemental disclosures include corrected CalciMedica financial projections (revenue starting FY2028) and Piper Sandler analysis.
Piper Sandler to receive $3M fee for merger advisory; $100K retainer and $750K opinion fee already earned.
Four stockholder lawsuits and nine demand letters allege proxy statement omissions; Graybug believes claims without merit.

item 5.02 item 8.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Parisa Zamiri

Chief Medical Officer

CALC · CalciMedica, Inc.

Effective: 2023-02-28
Filed: March 3, 2023, 6:59 PM ET

On February 28, 2023, the Board of Directors of Graybug Vision, Inc. (“Graybug”) determined it to be in Graybug’s best interests to terminate Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Parisa Zamiri was terminated as Chief Medical Officer at CalciMedica, Inc..

Action: terminated
Role: Chief Medical Officer

Exact text from the filing

On February 28, 2023, the Board of Directors of Graybug Vision, Inc. (“Graybug”) determined it to be in Graybug’s best interests to terminate Parisa Zamiri’s employment in advance of the anticipated closing date of the Merger

View on SEC.gov

CalciMedica, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-059999

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.